跳至主要内容
临床试验/JPRN-jRCT2033210646
JPRN-jRCT2033210646招募中3 期

Phase-III Comparative Study of EVA-001 for Osteoarthritis of the Knee

ee Antonio0 个研究点目标入组 130 人开始时间: 2022年3月6日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
130

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 < 80age old(—)
性别
All

入选标准

  • •Patients who meet all of the following criteria will be included.
  • •1) Men and women between the ages of 20 and less than 80 years
  • •2) Patients with a K&L Grade of 2 to 3 based on simple X-ray examination
  • •3) Patients with ICRS Grade 3 or 4 cartilage damage or deficiency in the knee joint as determined by magnetic resonance imaging (MRI) during the screening phase or by examination within the past 3 months
  • •4) Patients with lesions of 2-9 cm2 that are the main cause of clinical symptoms as a result of MRI evaluation
  • •5) Patients with FTA greater than 174 degrees and less than 180 degrees
  • •6) Patients with pain of 40 mm or more on the 100 mm VAS Scale
  • •7) Patients with a BMI of 35 kg/m2 or less
  • •8) Patients who have not responded to conservative therapy for more than 3 months
  • •9) For women of childbearing potential, patients who agree to maintain contraceptive status for the duration of the study
  • •10) Patients who have voluntarily decided to participate in the trial and have signed the consent form

排除标准

  • •Patients who meet any of the following criteria shall be excluded.
  • •1) Patients with autoimmune diseases or a history of autoimmune diseases
  • •2) Patients with infections requiring parenteral antibiotics or suspected of having such infections
  • •3) Patients with serious cardiovascular disease (myocardial infarction, congestive heart failure, uncontrolled hypertension, or other serious cardiac disease) or a history of such disease
  • •4) Patients with gout or suspected gout
  • •5) Patients with blood clotting abnormalities
  • •6) Patients with serious renal function abnormalities
  • •7) Patients with serious liver damage
  • •8) Patients with serious medical conditions
  • •9) Patients with malignancy or suspected malignancy
  • •10) Patients who are pregnant or currently breastfeeding
  • •11) Patients who have received intra-articular drugs such as hyaluronic acid injections within the past 8 weeks
  • •12) Patients with mental disorders or a history of mental disorders
  • •13) Patients who are habitual drinkers and are dependent or suspected of being alcoholic
  • •14) Patients with nicotine dependence or suspected nicotine dependence
  • •15) Patients with chronic inflammatory joint diseases (e.g., rheumatoid arthritis)
  • •16) Patients who have received immunosuppressive drugs such as cyclosporine A or azathioprine within the past 6 weeks
  • •17) Patients with dynamic injuries to the anterior cruciate ligament, posterior cruciate ligament, medial collateral ligament, and lateral collateral ligament of the knee
  • •18) Patients who are scheduled to undergo surgical treatment of the target knee joint, such as treatment for meniscus injury or ligament reconstruction, or who have undergone such surgical treatment within the past 6 months.
  • •19) Patients with paralysis due to nerve or muscle disease on the side of the knee joint cartilage damage or defect (affected side of the leg)
  • •20) Patients with a history of serious hypersensitivity to bovine-derived or porcine-derived ingredients of this product
  • •21) Patients with a history of severe hypersensitivity or anaphylactic shock to gentamicin
  • •22) Patients with a history of severe hypersensitivity or anaphylaxis to sodium hyaluronate or products containing hyaluronate
  • •23) Patients with a history of blood transfusion or transplantation
  • •24) Patients who have participated in another clinical trial within the past 3 month
  • •25) Patients who have been at rest for a long period of time within the past 3 months
  • •26) Patients with a history of contraindications to cartilage magnetic resonance (MRI) or contrast media if used
  • •27) Other patients who are determined to be unsuitable by the investigator or sub-investigator

研究者

发起方
ee Antonio

相似试验

Phase-III Comparative Study of EVA-001 for... | 临床试验